TY - JOUR
T1 - Tumor-targeting salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice
AU - Hiroshima, Yukihiko
AU - Zhao, Ming
AU - Zhang, Yong
AU - Zhang, Nan
AU - Maawy, Ali
AU - Murakami, Takashi
AU - Mii, Sumiyuki
AU - Uehara, Fuminari
AU - Yamamoto, Mako
AU - Miwa, Shinji
AU - Yano, Shuya
AU - Momiyama, Masashi
AU - Mori, Ryutaro
AU - Matsuyama, Ryusei
AU - Chishima, Takashi
AU - Tanaka, Kuniya
AU - Ichikawa, Yasushi
AU - Bouvet, Michael
AU - Endo, Itaru
AU - Hoffman, Robert M.
N1 - Funding Information:
This study was supported in part by National Cancer Institute grant numbers CA183280 and JSPS KAKENHI grant numbers 26830081 to YH, 26462070 to IE and 24592009 to KT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
Copyright: © 2015 Hiroshima et al.
PY - 2015/8/3
Y1 - 2015/8/3
N2 - A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemoresistant soft-tissue sarcoma.
AB - A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemoresistant soft-tissue sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=84942103142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942103142&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0134324
DO - 10.1371/journal.pone.0134324
M3 - Article
C2 - 26237416
AN - SCOPUS:84942103142
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 8
M1 - e0134324
ER -